News for hackers. Stuff that matters.
Re:Conclusions from analyzing Y Combinator’s investing history by sjg007 on Friday December 27, 2019 @07:57PM (#21896263)
Biotech is a long and winding road. Going through the YC startup list from the beginning, a lot of the startups are either out of business (ubiome), some variant of snake oil, or an AI mashup for lead generation. Then there are a whole host liquid biopsy new entrants which is an extremely competitive space. The lab management software one seems the most promising actually since it is an established market.

https://blogs.sciencemag.org/pipeline/archives/2018/07/17/th...

Re:Conclusions from analyzing Y Combinator’s investing history by wolco on Saturday December 28, 2019 @01:25AM (#21897495)
Ubiome patients sold for 7 million two weeks ago.

Bad management but great idea.

Re:Conclusions from analyzing Y Combinator’s investing history by sjg007 on Saturday December 28, 2019 @08:38AM (#21898815)
Sounds like they overpaid.
Re:Conclusions from analyzing Y Combinator’s investing history by DrAwdeOccarim on Saturday December 28, 2019 @07:16AM (#21898507)
Ginkgo is doing very well.
Re:Conclusions from analyzing Y Combinator’s investing history by sjg007 on Saturday December 28, 2019 @08:36AM (#21898804)
how so?